| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which …
Over the last 12 months, insiders at Inovio Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Inovio Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Inovio Pharmaceuticals, Inc. have bought $0 and sold $65,969 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 22,500 shares for transaction amount of $69,975 was made by Kim Jong Joseph (Chief Executive Officer) on 2020‑01‑13.
| 2023-06-05 | Sale | Zoth Lota S. | director | 5,700 0.0021% | $0.56 | $3,192 | -10.53% | |
| 2023-03-13 | Sale | Weiner David B. | director | 5,833 0.0022% | $1.15 | $6,708 | -57.50% | |
| 2023-02-27 | Sale | Weiner David B. | director | 11,668 0.0047% | $1.28 | $14,935 | -58.87% | |
| 2022-08-11 | Sale | Weiner David B. | 11,875 0.0051% | $2.66 | $31,588 | -37.80% | ||
| 2022-07-20 | Sale | BENITO SIMON X | 2,000 0.0008% | $2.25 | $4,500 | -26.91% | ||
| 2022-05-13 | Sale | Weiner David B. | 9,000 0.0037% | $1.95 | $17,550 | -11.06% | ||
| 2022-05-13 | Sale | Zoth Lota S. | 3,600 0.0015% | $1.98 | $7,128 | -11.06% | ||
| 2022-03-16 | Sale | BENITO SIMON X | 2,000 0.0009% | $3.16 | $6,320 | -42.12% | ||
| 2022-03-11 | Sale | Weiner David B. | 4,083 0.0019% | $3.20 | $13,066 | -40.53% | ||
| 2022-03-08 | Sale | Weiner David B. | 4,083 0.0019% | $3.33 | $13,596 | -40.80% | ||
| 2022-01-19 | Sale | BENITO SIMON X | director | 2,000 0.0009% | $4.27 | $8,540 | -49.88% | |
| 2022-01-05 | Sale | Zoth Lota S. | director | 961 0.0005% | $5.01 | $4,815 | -54.39% | |
| 2021-08-09 | Sale | Humeau Laurent | Chief Scientific Officer | 10,317 0.0047% | $9.15 | $94,401 | -60.42% | |
| 2021-06-09 | Sale | KIES PETER | CFO | 33,750 0.0161% | $10.01 | $337,838 | -37.39% | |
| 2021-06-09 | Sale | Humeau Laurent | Chief Scientific Officer | 10,318 0.0045% | $9.07 | $93,584 | -37.39% | |
| 2021-06-09 | Sale | Shea Jacqueline Elizabeth | Chief Operating Officer | 38,535 0.0184% | $10.01 | $385,735 | -37.39% | |
| 2021-06-03 | Sale | KIES PETER | CFO | 10,000 0.0049% | $8.03 | $80,300 | -17.24% | |
| 2021-05-17 | Sale | Weiner David B. | director | 3,045 0.0014% | $6.62 | $20,158 | 0.00% | |
| 2021-05-17 | Sale | BENITO SIMON X | director | 3,045 0.0014% | $6.62 | $20,158 | 0.00% | |
| 2021-05-17 | Sale | Zoth Lota S. | director | 2,045 0.001% | $6.62 | $13,538 | 0.00% |
| Kim Jong Joseph | Chief Executive Officer | 1078313 1.5607% | $1.79M | 17 | 13 | +45.42% |
| DHILLON AVTAR S | Executive Chairman | 233332 0.3377% | $387,331.12 | 2 | 0 | <0.0001% |
| KIES PETER | CFO | 130788 0.1893% | $217,108.08 | 5 | 10 | +7.37% |
| BENITO SIMON X | 75305 0.109% | $125,006.30 | 2 | 11 | <0.0001% | |
| Humeau Laurent | Chief Scientific Officer | 68587 0.0993% | $113,854.42 | 2 | 5 | +94.39% |
| Bagarazzi Mark | Chief Medical Officer | 60000 0.0868% | $99,600.00 | 1 | 0 | +283.31% |
| COLLINS MORTON | director | 50000 0.0724% | $83,000.00 | 11 | 0 | +3.14% |
| Sardesai Niranjan | Chief Operating Officer | 48434 0.0701% | $80,400.44 | 4 | 1 | +87.93% |
| Cabrera Angel | director | 36750 0.0532% | $61,005.00 | 3 | 0 | +73.94% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$16,280,851 | 76 | 1.48% | $118.27M | |
Inovio Pharmaceuticals, Inc. (INO) | $4,898,715 | 46 | 40.75% | $114.69M |
$130,095 | 43 | 45.19% | $111.24M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 45 | +36.59% | 16M | +77.51% |
| Decreased Positions | 44 | -35.77% | 4M | -19.52% |
| New Positions | 20 | New | 3M | New |
| Sold Out Positions | 22 | Sold Out | 625,498 | Sold Out |
| Total Postitions | 124 | +0.81% | 33M | +57.99% |
| Adage Capital Partners Gp, L.L.C. | $5,794.00 | 4.97% | 3.43M | +3M | New | 2025-09-30 |
| Janus Henderson Group Plc | $5,520.00 | 4.73% | 3.27M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $4,585.00 | 3.93% | 2.71M | +703,727 | +35.03% | 2025-09-30 |
| Boxer Capital Management, Llc | $3,887.00 | 3.33% | 2.3M | +2M | New | 2025-09-30 |
| Millennium Management Llc | $3,334.00 | 2.86% | 1.97M | +2M | +468.67% | 2025-09-30 |
| Renaissance Technologies Llc | $1,380.00 | 1.18% | 816,339 | +488,210 | +148.79% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $1,363.00 | 1.17% | 806,742 | +806,742 | New | 2025-09-30 |
| Morgan Stanley | $1,330.00 | 1.14% | 786,774 | +384,912 | +95.78% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,075.00 | 0.92% | 636,061 | -634,546 | -49.94% | 2025-09-30 |
| Geode Capital Management, Llc | $924.00 | 0.79% | 546,747 | +109,198 | +24.96% | 2025-09-30 |